REVBW
Revelation Biosciences IncNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-4.77
Beta
-0.14
52W High
$0.02
52W Low
$0.01
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Revelation Biosciences Inc
Revelation Biosciences Inc is an innovative biotechnology company dedicated to developing cutting-edge therapeutic solutions for respiratory diseases, including allergies and asthma. Leveraging its proprietary research platform, the firm is geared towards addressing significant unmet medical needs through its forward-thinking R&D initiatives. With a focus on enhancing patient outcomes, Revelation actively partners with industry stakeholders while adeptly navigating the regulatory landscape inherent in biopharmaceutical development. Supported by a promising pipeline of therapies, the company is well-positioned to deliver transformative impacts for patients suffering from respiratory conditions.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-10.04M |
| Operating Margin | 0.00% |
| Return on Equity | -124.40% |
| Return on Assets | -66.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.59 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $3.44M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
12.72%
HV 20-Day
68.29%
HV 30-Day
55.28%
HV 60-Day
67.91%
HV Rank
—
Volatility is currently contracting
Data last updated: 5/25/2026